CMRA (Comera Life Sciences Holdings) ROE %: 0.00% (As of Sep. 2023)


What is Comera Life Sciences Holdings ROE %?

Comera Life Sciences Holdings CMRA ROE % is 0.00% as of Sep. 2023.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Comera Life Sciences Holdings's annualized net income for the quarter that ended in Sep. 2023 was $-8.62 Mil. Comera Life Sciences Holdings's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-5.29 Mil. Therefore, Comera Life Sciences Holdings's annualized ROE % for the quarter that ended in Sep. 2023 was N/A%.

The historical rank and industry rank for Comera Life Sciences Holdings's ROE % or its related term are showing as below:

CMRA's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.11
* Ranked among companies with meaningful ROE % only.

Comera Life Sciences Holdings  (OTCPK:CMRA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-8.616/-5.2855
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.616 / 0.544)*(0.544 / 2.706)*(2.706 / -5.2855)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1583.82 %*0.201*N/A
=ROA %*Equity Multiplier
=-318.35 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-8.616/-5.2855
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-8.616 / -8.616) * (-8.616 / -8.628) * (-8.628 / 0.544) * (0.544 / 2.706) * (2.706 / -5.2855)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9986 * -1586.03 % * 0.201 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Comera Life Sciences Holdings ROE % Related Terms

Comera Life Sciences Holdings ROE % Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings ROE % Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
ROE %
-1,398.03 0.00 0.00

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CMRA vs FREQ, BNTC, IMNN: ROE % Comparison

For the Biotechnology subindustry, Comera Life Sciences Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's ROE % falls into.


Comera Life Sciences Holdings ROE % Calculation

Comera Life Sciences Holdings's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-18.004/( (-14.686+-6.247)/ 2 )
=-18.004/-10.4665
=N/A %

Comera Life Sciences Holdings's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-8.616/( (-6.35+-4.221)/ 2 )
=-8.616/-5.2855
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Comera Life Sciences Holdings (CMRA) has a ROE % of 0.00% as of Sep. 2023. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' ROE % too high?
Comera Life Sciences Holdings' current ROE % is 0.00%.
How does Comera Life Sciences Holdings' ROE % compare to FREQ and BNTC?
Comera Life Sciences Holdings' ROE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current ROE % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.